Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 9 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Orion Corporation has 10 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 10 distinct examiners and 9 distinct art units, indicating that prosecution is spread across several examination assignments rather than concentrated in one unit.
PARK, HAEJIN S is the busiest examiner, with 1 pending matter. Because that figure is lower than the total pending workload, the principal management issue is coordination across the examiner and art-unit assignments. Counsel may benefit from maintaining a consolidated response calendar while tailoring arguments to the different examination contexts.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (10%) |
| Double-patenting + other | 3 (30%) |
| Multi-statute (no §101) | 6 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PARK, HAEJIN S | 1 | 55.1% | +38.3% |
| COUGHLIN, MATTHEW P | 1 | 71.3% | +12.5% |
| WELLES, COLMAN THOMAS | 1 | 26.9% | +65.7% |
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| RAMACHANDRAN, UMAMAHESWARI | 1 | 54.8% | +53.7% |
| SAMSELL, RILLA MARIE | 1 | 69.1% | +6.4% |
| ABDALHAMEED, MANAHIL MIRGHANI ALI | 1 | 50.3% | +39.1% |
| BARSKY, JARED | 1 | 50.3% | +22.8% |
| BERHANE, SELAM | 1 | 59.1% | +56.4% |
| HUANG, GIGI GEORGIANA | 1 | 31.8% | +30.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19237260 | PHARMACEUTICAL COMPOSITION OF DAROLUTAMIDE | PARK, HAEJIN S | — |
| 18832210 | NOVEL SULFATE SALT FORMS OF ISOCHROMAN-IMIDAZOLE STRUCTURED ALPHA-2A ADRENOCEPTOR AGONIST | COUGHLIN, MATTHEW P | — |
| 18730692 | PHARMACEUTICAL COMPOSITION OF A CYP11A1 INHIBITOR | WELLES, COLMAN THOMAS | — |
| 18573360 | PROCESS FOR THE PREPARATION OF A CYP11A1 INHIBITOR AND INTERMEDIATES THEREOF | SAMSELL, RILLA MARIE | — |
| 18257761 | CHIMERIC ANTIGEN RECEPTOR (CAR) SPACER MODIFICATIONS ENHANCE CAR T CELL FUNCTIONALITY | BERHANE, SELAM | — |
| 17796691 | STABLE PHARMACEUTICAL COMPOSITIONS OF ROPINIROLE | HUANG, GIGI GEORGIANA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18548487 | NOVEL SALT FORMS OF A 4H-PYRAN-4-ONE STRUCTURED CYP11A1 INHIBITOR | BARSKY, JARED | 72d |
| 19237260 | PHARMACEUTICAL COMPOSITION OF DAROLUTAMIDE | PARK, HAEJIN S | — |
| 18832210 | NOVEL SULFATE SALT FORMS OF ISOCHROMAN-IMIDAZOLE STRUCTURED ALPHA-2A ADRENOCEPTOR AGONIST | COUGHLIN, MATTHEW P | — |
| 18730692 | PHARMACEUTICAL COMPOSITION OF A CYP11A1 INHIBITOR | WELLES, COLMAN THOMAS | — |
| 18708157 | CYP11A1 INHIBITORS | MOU, LIYUAN | — |
| 18704868 | SALT FORMS OF A 4H-PYRAN-4-ONE STRUCTURED CYP11 A1 INHIBITOR | RAMACHANDRAN, UMAMAHESWARI | — |
| 18548489 | SOLID FORMS OF A 4H-PYRAN-4-ONE STRUCTURED CYP11A1 INHIBITOR | ABDALHAMEED, MANAHIL MIRGHANI ALI | — |
| 18257761 | CHIMERIC ANTIGEN RECEPTOR (CAR) SPACER MODIFICATIONS ENHANCE CAR T CELL FUNCTIONALITY | BERHANE, SELAM | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1614 | 1 |
| 1626 | 1 |
| 1612 | 1 |
| 1627 | 1 |
| 1624 | 1 |
| 1622 | 1 |
| 1675 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19237260 | PHARMACEUTICAL COMPOSITION OF DAROLUTAMIDE | PARK, HAEJIN S | 1614 | §103§112Other | Final Rejection | — | Pending | Jun 13, 2025 |
| 18832210 | NOVEL SULFATE SALT FORMS OF ISOCHROMAN-IMIDAZOLE STRUCTURED ALPHA-2A ADRENOCEPTOR AGONIST | COUGHLIN, MATTHEW P | 1626 | §103§112Other | Non-Final OA | — | Pending | Jul 23, 2024 |
| 18730692 | PHARMACEUTICAL COMPOSITION OF A CYP11A1 INHIBITOR | WELLES, COLMAN THOMAS | 1612 | §103§112 | Non-Final OA | — | Pending | Jul 19, 2024 |
| 18708157 | CYP11A1 INHIBITORS | MOU, LIYUAN | 1628 | §103§112DP | Non-Final OA | — | Pending | May 07, 2024 |
| 18704868 | SALT FORMS OF A 4H-PYRAN-4-ONE STRUCTURED CYP11 A1 INHIBITOR | RAMACHANDRAN, UMAMAHESWARI | 1627 | §103DP | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18573360 | PROCESS FOR THE PREPARATION OF A CYP11A1 INHIBITOR AND INTERMEDIATES THEREOF | SAMSELL, RILLA MARIE | 1624 | §103§112 | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18548489 | SOLID FORMS OF A 4H-PYRAN-4-ONE STRUCTURED CYP11A1 INHIBITOR | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103DP | Final Rejection | — | Pending | Aug 30, 2023 |
| 18548487 | NOVEL SALT FORMS OF A 4H-PYRAN-4-ONE STRUCTURED CYP11A1 INHIBITOR | BARSKY, JARED | 1628 | §103Other | Final Rejection | 72d | Pending | Aug 30, 2023 |
| 18257761 | CHIMERIC ANTIGEN RECEPTOR (CAR) SPACER MODIFICATIONS ENHANCE CAR T CELL FUNCTIONALITY | BERHANE, SELAM | 1675 | §102§112 | Non-Final OA | — | Pending | Jun 15, 2023 |
| 17796691 | STABLE PHARMACEUTICAL COMPOSITIONS OF ROPINIROLE | HUANG, GIGI GEORGIANA | 1613 | §102§103 | Final Rejection | — | Pending | Aug 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOrion Corporation has 10 pending office actions as of October 2026, spread across 9 art units and 10 examiners.
Haejin S Park has the most, with 1 of Orion Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
